This event has ended. Visit the official site or create your own event on Sched.

View analytic
Tuesday, June 28 • 10:30am - 11:45am
#208: Measuring Return on Engagement: An Interim Report on the DIA-Tufts CSDD Metrics Study

Sign up or log in to save this to your schedule and see who's attending!

Limited Capacity seats available

Component Type: Forum
Level: Intermediate
CE: CME 1.25; IACET 1.25; RN 1.25

The patient centricity movement has generated substantial activity within both the public and private sectors, but to date no quantitative data have been gathered on the adoption and impact of specific patient-centric initiatives implemented by pharmaceutical and biotechnology companies to support processes within the medical product life cycle. Similarly, no effort has been made to harmonize the patient centricity principles and draft guidance recommendations developed by public and public-private consortia with industry drug development practice and policy. DIA, in collaboration with Tufts Center for the Study of Drug Development (CSDD), have undertaken a comprehensive study to address these critical needs. In this forum, the Tufts CSDD-DIA team, along with industry representatives participating in the study, will describe the study objectives and approach as well as work to date. In addition, they will share interim observations and insights from preliminary data that have been gathered and analyzed.

Learning Objectives

Discuss current outcomes and effectiveness of patient engagement in the medical product life cycle; Identify the benefits of standard metrics to advance the practice of meaningful patient engagement in medical product development and approval processes; Describe the objectives and approach of the DIA-Tufts CSDD study; Discuss observations of the study based on data collected to date, including patient engagement practice, metrics in use, and barriers to robust patient engagement programs.


Mary Jo Lamberti
Elizabeth Lincoln, MA


Kathleen A. Foley, PhD

John Manganaro

Jeffrey W. Sherman, MD, FACP

Ellen Coleman

avatar for Mary Jo Lamberti

Mary Jo Lamberti

Senior Research Fellow, Tufts University
Mary Jo Lamberti manages multi-sponsored and grant funded research projects at the Tufts Center for the Study of Drug Development at Tufts University School of Medicine. She has extensive experience conducting research on biopharmaceutical industry practices and trends within CROs and sites.
avatar for Elizabeth Lincoln

Elizabeth Lincoln

Global Director of Engagement, DIA
Prior to DIA, Elizabeth spent 12 years in Human Capital consulting at Accenture and five years at Career Concepts, Inc. She has worked across industries and for Fortune 100 as well as small, family-owned businesses in human resources and organization development. Since joining DIA, she has become deeply involved in DIA's patient engagement initiatives.

avatar for Ellen Coleman

Ellen Coleman

Senior Vice President, Mark Krueger and Associates, Inc.
Ellen Coleman is senior vice president at Mark Krueger & Associates, Inc. She brings considerable experience working with patients with chronic and life-threatening illnesses. Prior to joining MK&A, Ellen was the executive vice president of EmergingMed, overseeing advocacy relations and patient-facing services for individuals with cancer searching for clinical trials. Ellen has received numerous awards including the Ronald & Patti Rosenfeld... Read More →
avatar for Kathleen Foley

Kathleen Foley

Senior Director, Pfizer Inc.
Kathleen A. Foley is a senior director and the Patient Centered Metrics Lead in the Global Health and Value Innovation Center at Pfizer, where she is responsible for the development of metrics contributing to the science of patient input. Dr. Foley has a master’s degree from the School of Public Health at the University of Michigan and a PhD in sociology and demography at the University of Pennsylvania.

John Manganaro

Deputy Director, Regulatory Policy and Intelligence, Bayer HealthCare Pharmaceuticals
John has over 20 years in the pharmaceutical industry in Medical and Regulatory Affairs. He has extensive experience with various topics ranging from medical information, safety, compliance, product quality, intelligence research and regulatory issues. John is currently Deputy Director, Regulatory Policy and Intelligence at Bayer for the US, Latin America and Canada. | John holds a Pharm.D. from the University of Nebraska and M.S. in... Read More →
avatar for Jeffrey Sherman

Jeffrey Sherman

Chief Medical Officer and Executive Vice President, Research and Development, Horizon Pharma, Inc.
Jeff has more than 20 years of experience in the pharmaceutical industry. He is President of the Drug Information Association (DIA) and a member of the Board of Directors. He also served as chairperson of the DIA 2008 Annual Meeting and received an Outstanding Service Award in 2001.

Tuesday June 28, 2016 10:30am - 11:45am
108B Pennsylvania Convention Center 1101 Arch Street, Philadelphia, PA 19107 USA